|Bid||6.50 x 800|
|Ask||0.00 x 1000|
|Day's Range||7.36 - 7.95|
|52 Week Range||4.43 - 8.62|
|Beta (3Y Monthly)||4.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.65|
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a non-exclusive distribution agreement with DNA.
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2018 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2018-- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced two new total RNA sequencing applications for the C1™ system. ...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2018-- Fluidigm Corporation and Visiopharm A/S today announced a co-marketing relationship to automate image analysis for Imaging Mass Cytometry™. Under the terms ...
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018-- Fluidigm Corporation and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to accelerate the development of checkpoint immunotherapies ...
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018-- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, announced today that the company’ s management team will participate in three ...
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Middlesex ...
Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced it will hold its 2nd Annual Imaging Mass Cytometry User Group Meeting September 10–11 at the Seattle Art Museum. In this exciting program preceding the World Molecular Imaging Congress, leading academic and pharmaceutical researchers will share new insights in health and disease uncovered with the use of Imaging Mass Cytometry™ (IMC). “The Hyperion™ Imaging System is having a palpable impact on translational and clinical research programs around the world,” said Chris Linthwaite, President and CEO of Fluidigm.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018-- Fluidigm Corporation today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted ...
Fluidigm (FLDM) delivered earnings and revenue surprises of -2.44% and 0.50%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The company that makes equipment to control fluids posted revenue of $26.4 million in the period, ...
Total revenue increases 11 percent to $26.4 million. Mass cytometry revenue growth of 32 percent. Total consumables revenue growth of 19 percent.
SOUTH SAN FRANCISCO, Calif., July 31, 2018-- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new full-length single-cell mRNA sequencing application for ...
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. Fluidigm is one of United States’s small-cap stocks that saw someRead More...
LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want access to our free earnings report on Thermo Fisher Scientific Inc. (NYSE: TMO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TMO. Thermo Fisher Scientific reported its first quarter fiscal 2018 operating and financial results on April 25, 2018. Additionally, the Company raised its revenue and earnings guidance for FY18.